Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

111.94 -0.01 (-0.01%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
63 64 Next >
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets. 
Via Benzinga
Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks
With therapeutics focused on slimming down skyrocketing, it’s time to consider these top weight-loss stocks. 
Via InvestorPlace
Forget Tesla: I Think This Stock Should Replace It in the "Magnificent Seven"
Tesla doesn't look very magnificent these days. But there's another stock that does. 
Via The Motley Fool
Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?
Encouraging results recently pushed the pharma stock up to new heights. 
Via The Motley Fool
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung... 
Via Talk Markets
Exposures Product Safety
The Top 3 Pharma Stocks to Buy in March2024
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge. 
Via InvestorPlace
Oprah Winfrey To Spotlight Weight Loss Drugs In New TV Special: Will 'Shame, Blame' Come To Drug Companies — Or Could They Get Another Lift?
Weight loss drugs could get an increased spotlight with a television special from legendary TV host Oprah Winfrey. 
Via Benzinga
Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage
Novo Nordisk's Wegovy receives FDA approval for expanded use, targeting a significant reduction in cardiovascular events and weight management. 
Via Benzinga
Exposures Product Safety
Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular Risk
Novo Nordisk stock slumped despite winning FDA approval for its Wegovy in reducing cardiovascular risks. 
Via Investor's Business Daily
Exposures Product Safety
3 Stock Winners That Are Up 1,000% or More in 2024
Dig deep enough, and find a story hot enough, and you can uncover potential stock winners up 1,000%. Here are three. 
Via InvestorPlace
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect significant weight loss and cardiovascular benefits. Phase 2 trial begins in late... 
Via Benzinga
Stock Market Rally Hits Fresh Highs As Nvidia, Novo Nordisk, Bitcoin Soar: Weekly Review
The Nasdaq and S&P 500 hit new all-time highs. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Are These 5 Undervalued Stocks Ready to Break Out?
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
Via MarketBeat
Retail Traders Ditch Tesla, Apple, Google For Pharma Stocks Like Ozempic-Maker Novo Nordisk And Eli Lilly: JPMorgan
Retail traders have been observed to be selling off their shares in the 'Magnificent Seven' tech stocks, with a noticeable shift towards pharmaceutical stocks, according to a recent report by... 
Via Benzinga
Cannabis With Ozempic, Wegovy, Other Weight-Loss Drugs: Here's What You Need To Know If You're Combining Them
The study which comes amid the expansion of legal cannabis in the U.S. and the increased popularity of weight-loss treatments addressed the growing use of Glucagon-like peptide-1 (GLP-1) receptor... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Top 3 ETFs to Buy in March 2024
Simplify your investment strategy through these top ETFs to buy, offering an excellent blend of diversification and upside. 
Via InvestorPlace
Topics ETFs
S&P 500 Reclaims All-Time Highs As Powell Hints At Rate Cuts, Nvidia Breaks $900, Bitcoin Nears Record Levels: What's Driving Market Thursday?
The S&P 500 soared past the 5,150-point mark during midday trading in New York, reclaiming its record-high territory set earlier in the week. 
Via Benzinga
Topics Stocks
Exposures US Equities
Insurance Coverage For Weight Loss Drugs - Cigna Unveils Efforts To Limit Health Plans/Employers Spending
Evernorth Health Services, a Cigna subsidiary, introduces a financial guarantee in its EncircleRx program offering predictability for employers and health plans. Highlights agreements with Novo Nordisk... 
Via Benzinga
Why Viking Therapeutics Stock Is Plunging Today
The sell-off could present a buying opportunity for aggressive investors willing to bet that the obesity market will be big enough for multiple winners. 
Via The Motley Fool
Why Novo Nordisk Stock Is Jumping Today (Hint: It's Not Because of Ozempic or Wegovy)
Novo Nordisk could have another successful obesity drug on the way. 
Via The Motley Fool
American Eagle Reports Upbeat Earnings, Joins Kroger, Burlington Stores And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is MindMed (MNMD) Stock Up 32% Today?
MindMed stock is heading higher on Thursday as MNMD investors celebrate it getting breakthrough designation from the FDA! 
Via InvestorPlace
NVO Stock Alert: Novo Nordisk Pops on New Weight-Loss Drug
Novo Nordisk stock is gaining on Thursday as NVO investors react to positive news from its new weight loss drug clinical trial. 
Via InvestorPlace
Novo Nordisk's Stock Hits 52-Week High After Highly Sought After Obesity Drug Trial Data
Explore Novo Nordisk's Capital Markets Day insights! Uncover early trial success of amycretin, a potential obesity drug, with 13.1% weight loss in Phase 1. Learn about its safety and upcoming Phase 2... 
Via Benzinga
Novo Nordisk Jumps On Strong Results For New Weight-Loss Drug
Amycretin showed a 13.1% weight loss after 12 weeks in a phase 1 trial. 
Via Investor's Business Daily
Ozempic Maker Novo Nordisk To Introduce Obesity Drug Wegovy In Japan, Acknowledging Country's Rising Weight Issue
Novo Nordisk, a Danish pharmaceutical company, is set to launch its weight-loss drug, Wegovy, in Japan. This move is in response to the rising obesity rates in the country. 
Via Benzinga
Trillion-Dollar Threshold: The Next 3 Stocks Ready to Rise
With a trillion-dollar valuation in sight, these three growth companies have stocks ready to rise to meet the challenge. 
Via InvestorPlace
Novo Nordisk's Semaglutide's Multi-Beneficial Effects: Weight Loss, Improved Metabolic Markers, Liver Fat Reduction in HIV-Related Liver Disease
Novo Nordisk's Semaglutide, a breakthrough in HIV and fatty liver disease research, shows a 31% average reduction in liver fat. Novo Nordisk's trial reveals significant benefits for kidney health. 
Via Benzinga
Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win
The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it. 
Via Investor's Business Daily
Exposures Product Safety
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as Eli Lilly and Novo Nordisk address production bottlenecks amid rising... 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
63 64 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback